EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
